| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 10mg | |||
| 25mg | |||
| 50mg | |||
| Other Sizes |
| Targets |
S1PR1:1690 nM (EC50); S1PR2:119 nM (EC50); S1PR3:1950 nM (EC50); S1PR4:>10 μM (EC50); S1PR5:>10 μM (IC50)
CYM5478 targets the sphingosine-1-phosphate receptor 2 (S1P2), a G-protein-coupled receptor that mediates the effects of the bioactive lipid sphingosine-1-phosphate (S1P). It acts as a potent agonist with an EC50 of 119 nM in a TGFα-shedding assay. The compound is selective for S1P2 over S1P1, S1P3, S1P4, and S1P5, with EC50 values of 119, 1,690, 1,950, >10,000, and >10,000 nM, respectively. |
|---|---|
| ln Vitro |
In comparison to the other S1P receptor subtypes (EC50 of 1690 nM, 1950 nM, >10 μM, >10 μM for S1P1, S1P3, S1P4, and S1P5, respectively), CYM-5478 activates S1P2 with an EC50 of 119 nM, has less than 25% efficacy, and exhibits ten-fold reduced potency[1]. When serum fasting promotes nutrient-deprivation stress, CYM-5478 (1, 10, 100, 1000, and 10,000 nM) increases C6 cell viability in a dose-dependent manner at concentrations above 100 nM. When 10% fetal bovine serum was present, this effect did not occur[1]. CYM-5478 (10 μM) considerably attenuates the increase of ROS in C6 cells exposed to Cisplatin (20 μM; for 24 hours), and it also induces a statistically significant, 3-fold increase in the EC50 of Cisplatin-mediated decrease [1]. When exposed to Cisplatin toxicity, brain cells are shielded by CYM-5478 (20 μM) but not breast cancer cells (EC50=4.54 μM for C6 glioma cells, 17 μM for GT1-7, 7.44 μM for SK-N-BE2, and 5.54 μM for CLU188)[2].
In vitro, CYM5478 acts as a potent and selective agonist of S1P2. It has been shown to reduce serum starvation-induced decreases in C6 rat glioma cell viability at concentrations of 0.1-10 µM. Additionally, it reduces the accumulation of reactive oxygen species (ROS) and apoptosis induced by cisplatin in C6 cells when used at a concentration of 10 µM. These findings suggest a neuroprotective effect. |
| ln Vivo |
Rats exposed to Cisplatin-mediated ototoxicity (3 mg/kg; ip; once a week for three weeks) are protected against by CYM-5478 (1 mg/kg/day; ip)[2]. When CYM-5478 (20 μM) is administered, neuromast viability loss caused by cisplatin is almost completely prevented. CYM-5478 guards against ototoxicity-related loss of hair cell viability in a zebrafish model[2].
No specific in vivo activity data is publicly available for CYM5478. As a research compound, its in vivo efficacy and pharmacokinetic properties have not been extensively reported. The compound's neuroprotective effects in vitro suggest potential applications in models of neurotoxicity or neurodegenerative diseases, but further studies are needed. |
| Enzyme Assay |
In cell-free receptor binding assays, CYM5478's activity is evaluated by measuring its affinity and potency at the S1P2 receptor. Membrane preparations from cells expressing the human S1P2 receptor are incubated with a radiolabeled ligand (e.g., [33P]S1P) and varying concentrations of the compound. The displacement of the radioligand is measured, and the Ki is calculated. The compound's selectivity for S1P2 over other S1P receptor subtypes is also assessed.
|
| Cell Assay |
In vitro cell-based experiments with CYM5478 typically involve cell lines expressing the S1P2 receptor, such as C6 rat glioma cells. Cells are treated with the compound in the presence or absence of stressors such as serum starvation or cisplatin. Cell viability is assessed using assays such as MTT or CellTiter-Glo. The accumulation of reactive oxygen species (ROS) is measured using fluorescent probes (e.g., DCFH-DA), and apoptosis is assessed by flow cytometry or caspase activity assays.
|
| Animal Protocol |
No specific in vivo animal protocols are publicly available for CYM5478. If in vivo studies were to be conducted, typical protocols might involve mouse models of neurotoxicity or cisplatin-induced neuropathy, where the compound would be administered, and neuronal survival and function would be assessed.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is publicly available for CYM5478. As a research compound, its absorption, distribution, metabolism, and excretion (ADME) properties have not been extensively characterized. The compound is a small molecule with a molecular weight of approximately 386.39 (estimated from the molecular formula C21H19F3N2O2).
|
| Toxicity/Toxicokinetics |
No specific toxicity data is publicly available for CYM5478. In cell-based assays, the compound shows neuroprotective effects at concentrations up to 10 µM, indicating a relatively low acute toxicity in vitro. The compound is for research use only and is not intended for human therapeutic applications. No systemic toxicity studies have been reported.
|
| References |
|
| Additional Infomation |
CYM5478 is a potent and selective S1P2 receptor agonist with an EC50 of 119 nM in a TGFα-shedding assay. Its molecular formula is C21H19F3N2O2 and its molecular weight is approximately 386.39. The compound is also known as CYM-5478 or CYM547. It is a valuable research tool for studying the role of S1P2 signaling in neuroprotection, cardiovascular biology, and cancer. It is not approved for clinical use.
|
| Molecular Formula |
C21H19F3N2O2
|
|---|---|
| Molecular Weight |
388.4
|
| Exact Mass |
388.139
|
| Elemental Analysis |
C, 64.94; H, 4.93; F, 14.67; N, 7.21; O, 8.24
|
| CAS # |
870762-83-7
|
| PubChem CID |
7802604
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
527.1±50.0 °C at 760 mmHg
|
| Flash Point |
272.6±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.558
|
| LogP |
3.82
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
665
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C([H])=C([H])C(N(C=1[H])C([H])([H])C(C1C([H])=C(C([H])([H])[H])N(C([H])([H])C2C([H])=C([H])C([H])=C([H])C=2[H])C=1C([H])([H])[H])=O)=O)(F)F
|
| InChi Key |
RGSGTUIDJXHTTO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19F3N2O2/c1-14-10-18(15(2)26(14)11-16-6-4-3-5-7-16)19(27)13-25-12-17(21(22,23)24)8-9-20(25)28/h3-10,12H,11,13H2,1-2H3
|
| Chemical Name |
1-[2-(1-Benzyl-2,5-dimethylpyrrol-3-yl)-2-oxoethyl]-5-(trifluoromethyl)pyridin-2-one
|
| Synonyms |
CYM5478 CYM 5478 CYM-5478
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5747 mL | 12.8733 mL | 25.7467 mL | |
| 5 mM | 0.5149 mL | 2.5747 mL | 5.1493 mL | |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
